Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?
Cooley M&A
JANUARY 22, 2025
That said, some industry participants still looked to capitalize on anticipated vulnerabilities in their competitors pipelines with meaningful M&A bets such as Eli Lillys $2.3 By 2030, more than 190 commercial drugs will lose patent exclusivity , putting at risk $236 billion in Big Pharma sales.
Let's personalize your content